GYNECOLOGIC CANCERS

Gynecologic Cancers

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.

The added overall survival benefit seen with intraperitoneal versus intravenous chemotherapy extends beyond 10 years for patients with ovarian cancer.

The oral combination of olaparib, a PARP inhibitor, and BKM120, a PI3K inhibitor, demonstrated to be safe and clinical beneficial in women with high-grade serous ovarian cancer, as well as patients with triple-negative breast cancer.

The treatment of patients with ovarian cancer has evolved from an approach focused on chemotherapy and surgery to one involving targeted therapies and monoclonal antibodies.

The FDA’s recent approval of olaparib for women with BRCA-mutated advanced ovarian cancer marks a significant therapeutic advance for women with the malignancy, but the specific indication is far too restrictive and the drug should be offered to many more patients.

Charles A. (Trey) Leath III, MD, associate professor, gynecologic oncology, University of Alabama Birmingham Cancer Center, discusses a study that examined clinical outcomes and quality of life in ovarian cancer.

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses a study which examined the impact of bevacizumab in ovarian cancer.

The chimeric antigen receptor (CAR) T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.

A new study has found that a psychosocial telephone counseling intervention helps improve mood and quality of life in cervical cancer survivors.

To gain insight into this novel approach and its potential benefit, Targeted Oncology interviewed Bradley J. Monk, MD, FACOG, FACS, who presented phase II results at the 2015 SGO's Annual Meeting on Women's Cancer.

Sharyn N. Lewin, MD, discusses the importance of screening patients with ovarian cancer for a BRCA mutation.

The FDA has granted a breakthrough therapy designation to the PARP1/2 inhibitor rucaparib for the treatment of women with BRCA-mutated advanced ovarian cancer.

Intraperitoneal (IP) chemotherapy offers a median 10-month survival advantage over IV chemotherapy for women with advanced ovarian cancer. Result from a retrospective analysis were recently published in the Journal of Clinical Oncology.

In mid-December of 2014, the FDA approved the BRACAnalysis CDx diagnostic test to accompany the use of Lynparza (olaparib) in advanced ovarian cancer.

In a single-institution randomized prospective controlled trial of women with advanced epithelial ovarian cancer, 52.6% of patients in the PDS study arm had major complications with an MSKCC score of 3 or greater.

The angiogenesis inhibitor cediranib demonstrated acceptable activity and a tolerable safety profile as a monotherapy for patients with recurrent or persistent endometrial cancer.

Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.

The addition fosbretabulin tromethamine to bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in pretreated patients with recurrent ovarian cancer enrolled in the phase II GOG186i study.

Circulating tumor cells have previously been reported to be prognostic in other solid tumors: can they become a prognostic biomarker in cervical cancer?

A triage algorithm may identify patients with presumed advanced ovarian cancer who represent preoperatively defined candidates for diagnostic laparoscopy.